Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.

Gentile G, Ceccarelli M, Micheli L, Tirone F, Cavallaro S.

Front Pharmacol. 2016 Nov 30;7:449. eCollection 2016.

2.

EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.

Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li N, He JM, Xie GF, Xie X, Liang HJ.

Oncotarget. 2016 Jul 5;7(27):41540-41558. doi: 10.18632/oncotarget.9236.

3.
4.

Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.

Zorniak M, Clark PA, Kuo JS.

J Neurosurg. 2015 Jan;122(1):69-77. doi: 10.3171/2014.9.JNS132373.

5.

Anti-cancer Therapies in High Grade Gliomas.

Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML.

Curr Proteomics. 2013 Sep;10(3):246-260.

6.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

7.

Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells.

Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang SS, Lin SH, Kahle KT, Kuo JS, Sun D.

Cell Physiol Biochem. 2012;30(1):33-48. doi: 10.1159/000339047. Epub 2012 Jun 8.

8.

Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival.

Zorniak M, Clark PA, Leeper HE, Tipping MD, Francis DM, Kozak KR, Salamat MS, Kuo JS.

Clin Cancer Res. 2012 Jul 1;18(13):3628-36. doi: 10.1158/1078-0432.CCR-12-0339. Epub 2012 May 15.

9.

Evaluation of cancer stem cell migration using compartmentalizing microfluidic devices and live cell imaging.

Huang Y, Agrawal B, Clark PA, Williams JC, Kuo JS.

J Vis Exp. 2011 Dec 23;(58):e3297. doi: 10.3791/3297.

10.

Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas.

Pulvirenti T, Van Der Heijden M, Droms LA, Huse JT, Tabar V, Hall A.

Cancer Res. 2011 Dec 1;71(23):7280-90. doi: 10.1158/0008-5472.CAN-11-1531. Epub 2011 Oct 11.

11.
12.

Microfluidics-based devices: New tools for studying cancer and cancer stem cell migration.

Huang Y, Agrawal B, Sun D, Kuo JS, Williams JC.

Biomicrofluidics. 2011 Mar 30;5(1):13412. doi: 10.1063/1.3555195.

13.
14.

The cancer stem cell paradigm: a new understanding of tumor development and treatment.

Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA, Kuo JS.

Expert Opin Ther Targets. 2010 Jun;14(6):621-32. doi: 10.1517/14712598.2010.485186. Review.

15.

The bright and the dark sides of DNA repair in stem cells.

Frosina G.

J Biomed Biotechnol. 2010;2010:845396. doi: 10.1155/2010/845396. Epub 2010 Apr 8. Review.

16.

Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.

Menendez P, Catalina P, Rodríguez R, Melen GJ, Bueno C, Arriero M, García-Sánchez F, Lassaletta A, García-Sanz R, García-Castro J.

J Exp Med. 2009 Dec 21;206(13):3131-41. doi: 10.1084/jem.20091050. Epub 2009 Dec 7.

17.

Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15.

Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, Fei Z, Zhen HN, You SW, Yang H.

Transl Oncol. 2009 Dec;2(4):247-57.

18.

The transcription factor ATF5: role in neurodevelopment and neural tumors.

Greene LA, Lee HY, Angelastro JM.

J Neurochem. 2009 Jan;108(1):11-22. doi: 10.1111/j.1471-4159.2008.05749.x. Epub 2008 Nov 15. Review.

Supplemental Content

Support Center